Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.
about
Regenerative medicine: Current therapies and future directionsFibroblast engraftment in the decellularized mouse lung occurs via a β1-integrin-dependent, FAK-dependent pathway that is mediated by ERK and opposed by AKTNanoscale strategies: treatment for peripheral vascular disease and critical limb ischemia.Comparison of a closed system to a standard open technique for preparing tissue-engineered vascular graftsControlled protein delivery in the generation of microvascular networks.Novel Association of miR-451 with the Incidence of TEVG Stenosis in a Murine Model.Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time.Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells.Paracrine exchanges of molecular signals between alginate-encapsulated pericytes and freely suspended endothelial cells within a 3D protein gel.3D engineered cardiac tissue models of human heart disease: learning more from our mice.Small-diameter vascular tissue engineering.Vascular tissue engineering: from in vitro to in situ.Computational modeling and engineering in pediatric and congenital heart disease.Tissue engineering vascular grafts a fortiori: looking back and going forward.Decellularization of Human Internal Mammary Artery: Biomechanical Properties and Histopathological Evaluation.The Heart and Great Vessels.Translational Challenges in Cardiovascular Tissue Engineering.Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures.Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies.Compositions Including Synthetic and Natural Blends for Integration and Structural Integrity: Engineered for Different Vascular Graft Applications.New technologies for surgery of the congenital cardiac defect.Clinical translation of tissue-engineered constructs for severe leg injuries.Syndecan-1 in mechanosensing of nanotopological cues in engineered materials.Human Pluripotent Stem Cells to Engineer Blood Vessels.The role of myeloid cell-derived PDGF-B in neotissue formation in a tissue-engineered vascular graft.Toward a patient-specific tissue engineered vascular graft.A perspective on molybdenum biocompatibility and antimicrobial activity for applications in implants
P2860
Q26776380-FF3FB763-D2E0-4051-9C6A-6547F6925C15Q28397455-0830011B-1AE4-4FCF-B4DC-16490F839E1BQ33864915-75839BDF-3CEE-4766-9B92-3F92BB5C25EAQ34920180-279E8C31-AC5E-47F5-A73A-E4F5CA6E4905Q35162409-DE2A162E-7641-40F4-AE03-EE2F7F6BF6A8Q36543417-F47A6ECF-C499-4DAF-BE6E-180FBC5A64C5Q36755949-7BEFA1A3-656C-4F77-97FC-980C8506645EQ37055304-98655BC5-3D80-4BC7-A116-DA1BECDC932FQ37340560-19F7AB9C-3BF6-4438-A1BF-A846CB87317EQ38072173-6BDCBCCD-2370-42F3-AEDA-7326D229CABAQ38108204-EE72ADE9-FBC6-4337-9DAD-5B2305CB7DBAQ38154848-9AFA4F81-B99B-4717-BEC5-B5ED6CACC589Q38253733-460A7A22-BBBD-46EC-93DE-26066D8E12C1Q38271812-BBB0B442-FDB1-4425-A456-0D7B75451893Q38652911-7341F320-4D74-4007-A26A-E10CDCB22139Q38746402-775D3D8A-A441-4E5A-A5E1-C443F039099FQ38747713-C38C3D9E-264D-4006-9B4F-1BC942479FB4Q38817264-0BAC67F8-1F76-46D1-B78C-4FF8975EE2EAQ39190689-C9751432-8C53-443A-94CF-B84E1367C34BQ39216764-563229B5-ADA1-4D1E-BD3D-4C065300E8D5Q39373690-BF80F953-29A2-4480-923D-9634667B2C16Q41558652-28C9AB01-D3DF-42BA-BC9B-3953243F5295Q47331122-0282D096-DA2B-40D3-8F7A-A9041B4FEAAAQ47393306-D0FEABE5-5515-4F15-88A5-9A2D4E3CA719Q50869516-B910306D-CE54-4E99-B646-D990DFCC614EQ52345373-8B2C1400-3143-4CDD-BF71-80F29F5C647FQ58325909-579CB5C1-EAF8-49EA-AB8A-D78CB65C53D2
P2860
Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Tissue-engineered vascular gra ...... to the clinic and back again.
@ast
Tissue-engineered vascular gra ...... to the clinic and back again.
@en
type
label
Tissue-engineered vascular gra ...... to the clinic and back again.
@ast
Tissue-engineered vascular gra ...... to the clinic and back again.
@en
prefLabel
Tissue-engineered vascular gra ...... to the clinic and back again.
@ast
Tissue-engineered vascular gra ...... to the clinic and back again.
@en
P2093
P2860
P356
P1476
Tissue-engineered vascular gra ...... to the clinic and back again.
@en
P2093
Mark W Maxfield
Spencer Church
Thomas Gilliland
Toshiharu Shinoka
Yuji Naito
P2860
P304
P356
10.2217/RME.12.12
P577
2012-05-01T00:00:00Z